Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
Conditions
Interventions
rFIXFc
Locations
49
United States
Research Site
Phoenix, Arizona, United States
Research Site
Sacramento, California, United States
Research Site
Aurora, Colorado, United States
Research Site
Atlanta, Georgia, United States
Research Site
Honolulu, Hawaii, United States
Research Site
Indianapolis, Indiana, United States
Start Date
December 8, 2011
Primary Completion Date
October 1, 2017
Completion Date
October 1, 2017
Last Updated
December 19, 2020
Lead Sponsor
Bioverativ Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions